Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2020 / Cilt: 28 - Sayı: 3

Drug-eluting balloon treatment in femoropopliteal in-stent restenosis of different lengths

Farklı uzunluklardaki femoropopliteal stent içi restenozun ilaç salgılayan balon ile tedavisi

Pages
460–466
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

None of thepatients required amputation.Conclusion: The length of in-stent restenosis in thefemoropopliteal arterial stents is an important predictor forrecurrent stenosis, when re-flow is achieved with drug-elutingballoons.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: In this study, we present one-year results of drugeluting balloon treatment of femoropopliteal in-stent restenosis.Methods: A total of 62 patients (48 males, 14 females; meanage 64.2±9.1 years; range, 54 to 81 years) who underwent drugeluting balloon stenting for femoropopliteal in-stent restenosisbetween August 2013 and October 2017 were included in thestudy.
📊
Key Findings & Data:Group/Class 1(n=17): narrowing 1/2 of the stent length, not totally occluded; andGroup/Class 3 (n=23): totally occluded.
💡
Conclusion & Impact:None of thepatients required amputation.Conclusion: The length of in-stent restenosis in thefemoropopliteal arterial stents is an important predictor forrecurrent stenosis, when re-flow is achieved with drug-elutingballoons.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: In this study, we present one-year results of drugeluting balloon treatment of femoropopliteal in-stent restenosis.Methods: A total of 62 patients (48 males, 14 females; meanage 64.2±9.1 years; range, 54 to 81 years) who underwent drugeluting balloon stenting for femoropopliteal in-stent restenosisbetween August 2013 and October 2017 were included in thestudy. The patients were classified into three groups based onthe narrowing length of stenosis in the stents. Group/Class 1(n=17): narrowing 1/2 of the stent length, not totally occluded; andGroup/Class 3 (n=23): totally occluded. In-stent restenosis wastreated with drug-eluting balloon treatment.Results: There was a significant difference among all classes interms of in-stent restenosis. The length of stenosis was a predictorfor in-stent restenosis. The mean stent length was 107.7±24.6 mmin Group 1, 164.6±17.9 mm in Group 2, and 180±19.3 mm inGroup 3. For non-occluded in-stent restenosis, restenosis rate atone year after balloon angioplasty was 47.1% in Group 1, 86.4%in Group 2, and 95.7% in Group 3. Femoropopliteal bypass wasperformed in five patients in whom treatment failed. None of thepatients required amputation.Conclusion: The length of in-stent restenosis in thefemoropopliteal arterial stents is an important predictor forrecurrent stenosis, when re-flow is achieved with drug-elutingballoons.

Özet

Amaç: Bu çalışmada femoropopliteal stent içi restenozun ilaç salgılayan balon ile tedavisinin bir yıllık sonuçları sunuldu. Ça­lış­ma pla­nı: Ağustos 2013 - Ekim 2017 tarihleri arasında femoropopliteal stent içi restenoz nedeniyle ilaç salgılayan stentleme yapılan toplam 62 hasta (48 erkek, 14 kadın; ort. yaş 64.2±9.1 yıl; dağılım, 54-81 yıl) çalışmaya alındı. Hastalar stentlerdeki darlığın daralma uzunluğuna göre üç gruba ayrıldı. Grup 1/Sınıf 1 (n=17): stent uzunluğunda 1/2 oranında daralma, total oklüzyon yok ve Grup 3/Sınıf 3 (n=23): total oklüzyon. Stent içi restenoz, ilaç salgılayan balon tedavisi ile tedavi edildi. Bulgular: Stent içi restenoz açısından tüm sınıflar arasında anlamlı bir fark vardı. Stenozun uzunluğu stent içi restenozun bir öngördürücüsü idi. Ortalama stent uzunluğu Grup 1ʼde 107.7±24.6 mm, Grup 2ʼde 164.6±17.9 mm ve Grup 3ʼte 180±19.3 mm idi. Tıkanık olmayan stent içi restenoz için balon anjiyoplasti sonrası birinci yılda restenoz oranı Grup 1ʼde %47.1, Grup 2ʼde %86.4 ve Grup 3’te %95.7 idi. Tedavinin başarısız olduğu beş femoropopliteal baypas yapıldı. Hiçbir hastaya amputasyon gerekmedi. So­nuç: Femoropopliteal arteriyel stentlerdeki stent içi restenoz uzunluğu, ilaç salgılayan balon ile yeniden akış sağlandığında, tekrarlayan stenozun önemli bir öngördürücüsüdür

🔖

Cite This Article

ÖZPAK, B., ÇAYIR, M. Ç. (2022). Drug-eluting balloon treatment in femoropopliteal in-stent restenosis of different lengths. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 28 - Sayı: 3, 460–466. https://ajindex.com/articles/423613

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ko YG, Ahn CM, Min PK, Lee JH, Yoon CH, Yu CW, et al. Baseline Characteristics of a Retrospective Patient Cohort in the Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA) Registry. Korean Circ J 2017;47:469-76
  2. Kahraman D, Şırlak M. Infrapopliteal Angioplasty in Critical Limb Ischemia. Damar Cer Derg 2016;25:11-6
  3. Brescia AA, Wickers BM, Correa JC, Smeds MR, Jacobs DL. Stenting of femoropopliteal lesions using interwoven nitinol stents. J Vasc Surg 2015;61:1472-8
  4. Ozpak B, Bozok S, Cayir MC. Thirty-six-month outcomes of drug-eluting balloon angioplasty in the infrapopliteal arteries. Vascular 2018;26:457-63
  5. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010;3:267-76
  6. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54
  7. Akgül E, Erdolu B, Vural Hakan A, Yümün G, Özyazıcıoğlu Fatih A. An evaluation of the effect of biodegradable stents on restenosis in the treatment of peripheral arterial lesions. Turk Gogus Kalp Dama 2017;25:203-8
  8. Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology 2004;232:516-21
  9. Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv 2014;7:411-5
  10. Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 2012;59:16-23
  11. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology 2002;222:37-43
  12. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv